Abstract

Many drug molecules can be directly used as nanomedicine without the requirement of any inorganic or organic carriers such as silica and liposome nanostructures. This new type of carrier-free drug nanoparticles (NPs) has great potential in clinical treatment because of its ultra-high drug loading capacity and biodegradability. For practical applications, it is essential for such nanomedicine to possess robust stability and minimal premature release of therapeutic molecules during circulation in the blood stream. To meet this requirement, herein, we develop GSH-responsive and crosslinkable amphiphilic polyethylene glycol (PEG) molecules to modify carrier-free drug NPs. These PEG molecules can be cross-linked on the surface of the NPs to endow them with greater stability and the cross-link is sensitive to intracellular environment for bio-responsive drug release. With this elegant design, our experimental results show that the liberation of DOX from DOX-cross-linked PEG NPs is dramatically slower than that from DOX-non-cross-linked PEG NPs, and the DOX release profile can be controlled by tuning the concentration of the reducing agent to break the cross-link between PEG molecules. More importantly, in vivo studies reveal that the DOX-cross-linked PEG NPs exhibit favorable blood circulation half-life (>4 h) and intense accumulation in tumor areas, enabling effective anti-cancer therapy. We expect this work will provide a powerful strategy for stabilizing carrier-free nanomedicines and pave the way to their successful clinical applications in the future.

Highlights

  • Cancer is a leading cause of death in all countries and chemotherapy has been widely used in combination with other treatments like radiotherapy for curing the disease

  • These polyethylene glycol (PEG) molecules can be cross-linked on the surface of the NPs to endow them with greater stability and the cross-link is sensitive to intracellular environment for bio-responsive drug release

  • Our experimental results show that the liberation of DOX from DOX-cross-linked PEG NPs is dramatically slower than that from DOX-noncross-linked PEG NPs, and the DOX release profile can be controlled by tuning the concentration of the reducing agent to break the cross-link between PEG molecules

Read more

Summary

Introduction

Cancer is a leading cause of death in all countries and chemotherapy has been widely used in combination with other treatments like radiotherapy for curing the disease. The stability, in vitro drug release, cytotoxicity, cellular uptake, blood circulation, biodistribution, and antitumor activity were systematically studied for different types of NPs including bare DOX NPs, DOX NPs coated with PEGA and PEGB (individually termed as DOX-NCLPEGA NPs and DOX-NCLPEGB NPs), as well as DOX NPs coated with crosslinked surfactant molecules (termed DOX-CLPEGA NPs and DOX-CLPEGB NPs). Compared with other NPs, the cross-linked surfactant modified DOX NPs show much better bio-stability, longer blood circulation time, and promoted drug delivery to tumor sites as a result of the adequately inhibited premature release of payload molecules.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.